If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for March 21 2014
Instant Access to Deep Knowledge on Small-Molecule
access to valuable datasets, including:
- Patent litigation
- Clinical trial information
- International patent data
- Paragraph IV challenges
- Tentative approvals
- Drug Master Files
- Dynamic search capabilities with data
More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.
The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
The April 1 2014 issue of the Journal of Commercial Biotechnology has just been published, and features the following papers: Building biotechnology in India – Drugs are not the answer Yali Friedman I have had the pleasure of participating in national forums on biotechnology development in diverse countries. A common theme I see is that […]
New books from the publisher of the Journal of CommercialBiotechnology
Biomedical and health entrepreneurship continues to expand around the world. Driven by global pressures to optimize the allocation of scarce resources, life science bioentrepreneurs are creating innovative products, platforms, service and systems that …
The prospect of government regulation, product liability lawsuits, and customer reliance on third-party payers contribute to the complexity of valuing biotech start-ups. In addition, the inherent complexity of biologic drug manufacturing and storage creates secondary risks that must be considered in a valuation.
The purpose of this study was to test the unexplored relationship between market orientation (MO), alliance orientation (AO), and business performance (PERF) in the medical/healthcare subsector of the Canadian biotechnology industry. The study surveyed Canadian biotechnology executives via mail and web-based questionnaires. It was found that the relationship between MO and PERF was positive and significant and the relationship between AO and PERF was positive and significant. It was also found that the relationship between MO and AO was positive and significant, supporting the existence of a mediation relationship. Specifically, MO’s influence on PERF was found to be fully mediated by AO. This suggests that Canadian medical/healthcare biotechnology companies that were highly market-oriented were also highly alliance-oriented, and highly alliance-oriented companies were top performing companies. This study outlines the apparent sequential relationship between market-oriented behavioural commitments, alliance-oriented activities, and business performance outcomes among Canadian biotechnology companies. Furthermore, it has business development and the commercialization process implications for biotechnology managers.
This paper is an examination of the economics, organizational dynamics and structural factors inhibiting an electronic market for intellectual property. Several intermediaries exist to facilitate the transition of intellectual property (IP) from sellers to buyers. Over the past 20 years, a number of companies attempted to create an online “eBay for IP.” These IP Exchanges (IPEs) failed to gain traction in competition with other mediums that provide channels to facilitate IP transactions. Compounding the problem is the concentration of intellectual property assets amongst a small group of institutions and within those institutions as well as organizational hurdles inherent in academic technology transfer offices. As a result, the business model for an online IPE market is fundamentally challenging, and no successful IPE exists to date.
The growing share of biopharmaceuticals is paralleled by an increasing interest in biogenerics, as blockbuster biologics are approaching their patent expiries. Companies need to make decisions whether to invest in biosimilars or in biobetters with enhanced properties, the latter enabling favorable differentiation vis-à-vis the original product on the one hand and biosimilars on the other hand. Net present value (NPV) modelling was applied to evaluate the financial attractiveness of two categories of biobetters in comparison to biosimilars, and recommendations are made which options should be preferred depending on a company’s business model.
Canada plays a significant role in the global advancement of scientific discoveries and their translation into commercial opportunities, but is viewed as not fully realizing its commercial potential. A significant problem has been a lack of sufficient venture capital to take early-stage companies to the next level. Several recent developments may signal the arrival of a more positive venture-funding environment for life sciences and health technology enterprises, including the development of the Canadian government’s C$400 million Venture Capital Action Plan; pharmaceutical companies electing to establish or investing in venture funds and providing strategic support to early-stage ventures, including through the creation of research centres; and recent successful liquidity events for venture investors.
In recent years, the major research-intensive biopharmaceutical companies (big pharma) have come face to face with a perfect storm of eroding profit margins from blockbuster expiration and generic competition coupled with growing R&D expenses and d…